RxDoctor Payments Data

Colin Stokol, MD

Neurology · Los Angeles, CANPI 1184753212

Payments from drug & device makers

$4,123in general payments, 2019–2025

Across 178 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$882
  • Takeda Pharmaceuticals U.S.A., Inc.$796
  • AbbVie$406
  • Edwards Lifesciences$274
  • Aimmune Therapeutics, Inc.$240
  • Regeneron Healthcare Solutions, Inc.$169
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,06699%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,123 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$245,318
Medicare patients
959
Services billed
1,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate13$74,599
NamzaricMemantine Hcl/Donepezil Hcl27$19,019
Memantine Hcl436$15,965
Levetiracetam172$6,472
Lacosamide20$5,385
Rasagiline Mesylate17$3,800
Carbidopa-LevodopaCarbidopa/Levodopa111$3,376
Gabapentin163$2,752
Lamotrigine26$1,549
Divalproex Sodium29$1,412
Carbamazepine28$1,401
Pramipexole DihydrochloridePramipexole Di-Hcl31$1,325
Phenytoin Sodium Extended35$1,285
Memantine Hcl ErMemantine Hcl23$1,267
Pyridostigmine Bromide14$1,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric$406$19,01927 claims
Lilly USA, LLCOlanzapine$16$26912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →